Comment on “Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes : arget trial emulation using nationwide real‐world data in the US”

Comment on “Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes : arget trial emulation using nationwide real‐world data in the US”

Salehi-Abargouei, Amin (Research Center for Food Hygiene and Safety, Shahid Sadoughi University of Medical Sciences, Alem Square, Yazd, Iran ; Department of Nutrition, School of Public Health, Shahid Sadoughi University of Medical Sciences, Alem Square, Yazd, Iran ; Yazd Cardiovascular Research Center, Institute of Non-communicable Diseases, Shahid Sadoughi University of Medical Sciences, Jomhouri Eslami Blvd, Yazd, Iran)
Muka, Taulant (Epistudia, Schanzenstrasse, Bern, Switzerland)
Collet, Tinh-Hai (Service of Endocrinology, Diabetology, Nutrition and Therapeutic Education, Geneva University Hospitals, Geneva, Switzerland ; Diabetes Centre, Faculty of Medicine, University of Geneva, Geneva, Switzerland)
Kepp, Kasper P. (Epistudia, Schanzenstrasse, Bern, Switzerland)
Chatelan, Angeline (Geneva School of Health Sciences, HES-SO University of Applied Sciences and Arts Western Switzerland)

2025-05

Alzheimer's & dementia

2025, 21

5

e70035

États-Unis, John Wiley & Sons

2 p.

1552-5260

scientifique

Santé

HEdS - Genève

Institut de Recherche de la Haute école de santé de Genève IR-HEdS

Veröffentlichte Artikel
Global